How should we proceed with disease-modifying treatments for multiple sclerosis?
- PMID: 9057726
- DOI: 10.1016/S0140-6736(05)61562-0
How should we proceed with disease-modifying treatments for multiple sclerosis?
Comment on
-
Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group.Lancet. 1997 Mar 1;349(9052):589-93. doi: 10.1016/s0140-6736(96)09377-4. Lancet. 1997. PMID: 9057729 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
